[SCHEDULE 13D/A] Strata Skin Sciences, Inc. SEC Filing
Accelmed Partners and affiliated reporting persons disclose beneficial ownership of 1,441,835 shares of Strata Skin Sciences common stock, representing 27.4% of the outstanding shares. This Amendment No. 2 to Schedule 13D reports that the percentage calculation is based on 5,268,708 shares outstanding following a September 4, 2025 registered direct offering by the issuer that issued 1,097,547 new shares. The filing amends prior Schedule 13D information solely to reflect the change in percent of class; no transactions in the issuer's shares by the reporting persons occurred in the past 60 days. The reporting persons and signatory for this filing is Uri Geiger in his capacity as Managing Partner.
Accelmed Partners e le persone correlate riportanti detengono la propriet脿 beneficiaria di 1.441.835 azioni ordinarie di Strata Skin Sciences, pari al 27,4% delle azioni in circolazione. Questo Emendamento n. 2 al Modulo 13D indica che il calcolo percentuale si basa su 5.268.708 azioni in circolazione dopo un'offerta diretta registrata dell'emittente del 4 settembre 2025, che ha emesso 1.097.547 nuove azioni. Il deposito modifica le informazioni contenute nel precedente Modulo 13D esclusivamente per riflettere la variazione della percentuale della classe; nei precedenti 60 giorni non si sono verificate transazioni sulle azioni dell'emittente da parte delle persone riportanti. La persona segnalante e firmataria di questo deposito 猫 Uri Geiger nella sua veste di Managing Partner.
Accelmed Partners y las personas informantes afiliadas declaran la propiedad beneficiaria de 1.441.835 acciones ordinarias de Strata Skin Sciences, que representan el 27,4% de las acciones en circulaci贸n. Esta Enmienda n潞 2 al Anexo 13D informa que el c谩lculo porcentual se basa en 5.268.708 acciones en circulaci贸n despu茅s de una colocaci贸n directa registrada por el emisor el 4 de septiembre de 2025, que emiti贸 1.097.547 acciones nuevas. La presentaci贸n enmienda la informaci贸n previa del Anexo 13D 煤nicamente para reflejar el cambio en el porcentaje de la clase; no se registraron transacciones en las acciones del emisor por parte de las personas informantes en los 煤ltimos 60 d铆as. La persona informante y firmante de esta presentaci贸n es Uri Geiger en su calidad de Managing Partner.
Accelmed Partners 氚� 甏�霠� 鞁犼碃鞚胳潃 Strata Skin Sciences 氤错喌欤� 1,441,835欤检棎 雽�頃� 靷嫟靸� 靻岇湢毳� 瓿店皽頃橂┌, 鞚措姅 氚滍枆欤检嫕鞚� 27.4%鞐� 頃措嫻頃╇媹雼�. 氤� Schedule 13D鞚� 靾橃爼靹�(靾橃爼氩堩樃 2)電� 牍勳湪 瓿勳偘鞚� 2025雲� 9鞗� 4鞚� 氚滍枆靷皜 鞁れ嫓頃� 霌彪 歆侅爲 瓿惦 鞚错泟 鞙犿喌欤检嫕靾� 5,268,708欤茧ゼ 旮办鞙茧 頄堨溂氅�, 頃措嫻 瓿惦鞐愳劀 1,097,547欤检潣 鞁犾＜臧� 氚滍枆霅橃棃鞚岇潉 氤搓碃頃╇媹雼�. 氤� 鞝滌稖鞚� 霌标笁 牍勳湪鞚� 氤�瓴届潉 氚橃榿頃橁赴 鞙勴暣靹滊 鞚挫爠 Schedule 13D 鞝曤炒毳� 靾橃爼頃� 瓴冹澊氅�, 鞁犼碃鞚鸽摛鞚� 歆�雮� 60鞚� 霃欖晥 氚滍枆靷� 欤检嫕鞐� 雽�頃� 瓯半灅毳� 頃� 氚旊姅 鞐嗢姷雼堧嫟. 氤� 鞝滌稖鞚� 鞁犼碃鞚� 瓴� 靹滊獏鞚胳潃 毵る媹歆� 韺岉姼雱�(Managing Partner) 鞛愱博鞚� Uri Geiger鞛呺媹雼�.
Accelmed Partners et les personnes d茅clarantes affili茅es d茅clarent la propri茅t茅 b茅n茅ficiaire de 1 441 835 actions ordinaires de Strata Skin Sciences, repr茅sentant 27,4 % des actions en circulation. Cet Amendement n掳2 au Schedule 13D pr茅cise que le calcul en pourcentage est fond茅 sur 5 268 708 actions en circulation 脿 la suite d'une offre directe enregistr茅e par l'茅metteur le 4 septembre 2025, qui a 茅mis 1 097 547 nouvelles actions. Le d茅p么t modifie les informations du pr茅c茅dent Schedule 13D uniquement afin de refl茅ter le changement du pourcentage de la classe ; aucune transaction sur les actions de l'茅metteur par les personnes d茅clarantes n'a eu lieu au cours des 60 derniers jours. La personne d茅clarante et signataire de ce d茅p么t est Uri Geiger en sa qualit茅 de Managing Partner.
Accelmed Partners und zugeh枚rige meldende Personen geben den wirtschaftlichen Eigentum an 1.441.835 Aktien der Stammaktien von Strata Skin Sciences an, was 27,4% der ausstehenden Aktien entspricht. Diese 脛nderung Nr. 2 zu Schedule 13D berichtet, dass die Prozentberechnung auf 5.268.708 ausstehenden Aktien basiert, nach einem am 4. September 2025 durchgef眉hrten registrierten Direktangebot des Emittenten, bei dem 1.097.547 neue Aktien ausgegeben wurden. Die Einreichung 盲ndert fr眉here Schedule 13D-Angaben ausschlie脽lich, um die 脛nderung des Klassenanteils widerzuspiegeln; in den vergangenen 60 Tagen fanden seitens der meldenden Personen keine Transaktionen mit den Aktien des Emittenten statt. Meldende Person und Unterzeichner dieser Einreichung ist Uri Geiger in seiner Funktion als Managing Partner.
- Material disclosure of ownership: Reporting persons clearly disclose beneficial ownership of 1,441,835 shares representing 27.4% of outstanding common stock.
- Amendment transparency: Filing explicitly explains that the change in percent of class is due to the issuer's registered direct offering that issued 1,097,547 new shares.
- No recent transactions: Reporting persons state they have not engaged in any transactions in the issuer's shares during the past 60 days.
- None.
Insights
TL;DR: Accelmed and affiliates hold a material 27.4% stake after a dilution event; this is a significant ownership disclosure for SSKN shareholders.
The filing shows 1,441,835 shares beneficially owned by Accelmed-related reporting persons, representing 27.4% of Strata Skin Sciences' 5,268,708 shares outstanding after the issuer's September 4, 2025 registered direct offering that issued 1,097,547 shares. The amendment is limited to recalculating percent ownership and does not report any purchases or sales by the reporting persons in the last 60 days. For investors, a single disclosed holder at this ownership level can influence shareholder votes and strategic decisions, though the filing does not state any control actions or transactions.
TL;DR: The amendment corrects ownership percentages after issuance; it discloses significant stake but reports no change in holdings or governance actions.
The document amends prior Schedule 13D to reflect the issuer's new share count following a registered direct offering. Reporting persons continue to report shared voting and dispositive power over 1,441,835 shares. The filing contains no statements about plans, proposals or transactions and confirms no shares were transacted in the past 60 days. From a governance perspective, the filing provides necessary transparency but does not itself indicate any imminent board or strategic moves.
Accelmed Partners e le persone correlate riportanti detengono la propriet脿 beneficiaria di 1.441.835 azioni ordinarie di Strata Skin Sciences, pari al 27,4% delle azioni in circolazione. Questo Emendamento n. 2 al Modulo 13D indica che il calcolo percentuale si basa su 5.268.708 azioni in circolazione dopo un'offerta diretta registrata dell'emittente del 4 settembre 2025, che ha emesso 1.097.547 nuove azioni. Il deposito modifica le informazioni contenute nel precedente Modulo 13D esclusivamente per riflettere la variazione della percentuale della classe; nei precedenti 60 giorni non si sono verificate transazioni sulle azioni dell'emittente da parte delle persone riportanti. La persona segnalante e firmataria di questo deposito 猫 Uri Geiger nella sua veste di Managing Partner.
Accelmed Partners y las personas informantes afiliadas declaran la propiedad beneficiaria de 1.441.835 acciones ordinarias de Strata Skin Sciences, que representan el 27,4% de las acciones en circulaci贸n. Esta Enmienda n潞 2 al Anexo 13D informa que el c谩lculo porcentual se basa en 5.268.708 acciones en circulaci贸n despu茅s de una colocaci贸n directa registrada por el emisor el 4 de septiembre de 2025, que emiti贸 1.097.547 acciones nuevas. La presentaci贸n enmienda la informaci贸n previa del Anexo 13D 煤nicamente para reflejar el cambio en el porcentaje de la clase; no se registraron transacciones en las acciones del emisor por parte de las personas informantes en los 煤ltimos 60 d铆as. La persona informante y firmante de esta presentaci贸n es Uri Geiger en su calidad de Managing Partner.
Accelmed Partners 氚� 甏�霠� 鞁犼碃鞚胳潃 Strata Skin Sciences 氤错喌欤� 1,441,835欤检棎 雽�頃� 靷嫟靸� 靻岇湢毳� 瓿店皽頃橂┌, 鞚措姅 氚滍枆欤检嫕鞚� 27.4%鞐� 頃措嫻頃╇媹雼�. 氤� Schedule 13D鞚� 靾橃爼靹�(靾橃爼氩堩樃 2)電� 牍勳湪 瓿勳偘鞚� 2025雲� 9鞗� 4鞚� 氚滍枆靷皜 鞁れ嫓頃� 霌彪 歆侅爲 瓿惦 鞚错泟 鞙犿喌欤检嫕靾� 5,268,708欤茧ゼ 旮办鞙茧 頄堨溂氅�, 頃措嫻 瓿惦鞐愳劀 1,097,547欤检潣 鞁犾＜臧� 氚滍枆霅橃棃鞚岇潉 氤搓碃頃╇媹雼�. 氤� 鞝滌稖鞚� 霌标笁 牍勳湪鞚� 氤�瓴届潉 氚橃榿頃橁赴 鞙勴暣靹滊 鞚挫爠 Schedule 13D 鞝曤炒毳� 靾橃爼頃� 瓴冹澊氅�, 鞁犼碃鞚鸽摛鞚� 歆�雮� 60鞚� 霃欖晥 氚滍枆靷� 欤检嫕鞐� 雽�頃� 瓯半灅毳� 頃� 氚旊姅 鞐嗢姷雼堧嫟. 氤� 鞝滌稖鞚� 鞁犼碃鞚� 瓴� 靹滊獏鞚胳潃 毵る媹歆� 韺岉姼雱�(Managing Partner) 鞛愱博鞚� Uri Geiger鞛呺媹雼�.
Accelmed Partners et les personnes d茅clarantes affili茅es d茅clarent la propri茅t茅 b茅n茅ficiaire de 1 441 835 actions ordinaires de Strata Skin Sciences, repr茅sentant 27,4 % des actions en circulation. Cet Amendement n掳2 au Schedule 13D pr茅cise que le calcul en pourcentage est fond茅 sur 5 268 708 actions en circulation 脿 la suite d'une offre directe enregistr茅e par l'茅metteur le 4 septembre 2025, qui a 茅mis 1 097 547 nouvelles actions. Le d茅p么t modifie les informations du pr茅c茅dent Schedule 13D uniquement afin de refl茅ter le changement du pourcentage de la classe ; aucune transaction sur les actions de l'茅metteur par les personnes d茅clarantes n'a eu lieu au cours des 60 derniers jours. La personne d茅clarante et signataire de ce d茅p么t est Uri Geiger en sa qualit茅 de Managing Partner.
Accelmed Partners und zugeh枚rige meldende Personen geben den wirtschaftlichen Eigentum an 1.441.835 Aktien der Stammaktien von Strata Skin Sciences an, was 27,4% der ausstehenden Aktien entspricht. Diese 脛nderung Nr. 2 zu Schedule 13D berichtet, dass die Prozentberechnung auf 5.268.708 ausstehenden Aktien basiert, nach einem am 4. September 2025 durchgef眉hrten registrierten Direktangebot des Emittenten, bei dem 1.097.547 neue Aktien ausgegeben wurden. Die Einreichung 盲ndert fr眉here Schedule 13D-Angaben ausschlie脽lich, um die 脛nderung des Klassenanteils widerzuspiegeln; in den vergangenen 60 Tagen fanden seitens der meldenden Personen keine Transaktionen mit den Aktien des Emittenten statt. Meldende Person und Unterzeichner dieser Einreichung ist Uri Geiger in seiner Funktion als Managing Partner.
FAQ
What stake does Accelmed Partners report in Strata Skin Sciences (SSKN)?
Why was this Schedule 13D/A filed for SSKN?
Did the reporting persons buy or sell SSKN shares recently?
Who signed the Schedule 13D/A for Accelmed?
How many shares did Strata Skin Sciences issue in the registered direct offering?
